Document is current
Any future updates will be listed below
-
Authors
Peng, Hengxin
Zhang, Wenjun
Lin, Yanqing
Li, Huiming
Qin, Suofu https://orcid.org/0000-0002-3323-8846
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06277167 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, Tolerability, and Pharmacokinetics of Nebulized GB05-Human IFNα1b Inhalation Solution: A Randomized, Placebo-Controlled, Dose-Escalation Phase I Study in Healthy Chinese Adult Volunteers
https://doi.org/10.1007/s40121-024-01024-y
-
Funding
Funding for this research was provided by:
Shenzhen Kexing Biopharm Co., Ltd.
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 24 July 2024
First Online: 4 August 2024
Declarations
:
: Hengxin Peng, Wenjun Zhang, Yanqing Lin, Huiming Li and Suofu Qin are employees of Shenzhen Kexing Biopharm Co., Ltd. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: The study protocol and informed consent forms were approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of the Third Hospital of Changsha (Approval number CS3-2022EC-065). This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided written informed consent for this study.
